Back to today’s briefing

Story perspectives

Novo Nordisk Faces $125B Loss Amid Obesity Drug Trials

2/6/2025

41 4

Summary

Novo Nordisk Struggles

Novo Nordisk's CagriSema obesity drug is under fire after trial results fell short, causing a staggering $125 billion drop in market value. Yet, the company holds onto hope, eyeing a new trial in 2025. In contrast, Wegovy's soaring sales in 2024 bolster Novo's stronghold in the competitive obesity treatment landscape.

Summary

Novo Nordisk's Setback

Novo Nordisk's hopes for monlunabant, a cannabinoid CB1 receptor blocker, took a hit as it flunked a phase 2 trial for diabetic kidney disease, failing to show any meaningful improvement in kidney function. While most side effects were mild to moderate, an uptick in neuropsychiatric issues raised concerns. The company, however, is still eyeing its weight loss potential.

1 of 2

Novo Nordisk Struggles

Novo Nordisk's CagriSema obesity drug is under fire after trial results fell short, causing a staggering $125 billion drop in market value. Yet, the company holds onto hope, eyeing a new trial in 2025. In contrast, Wegovy's soaring sales in 2024 bolster Novo's stronghold in the competitive obesity treatment landscape.

1 / 2